| Document |
Document Title |
|
JP2004512255A |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
JP2004107275A |
To provide an antimicrobial peptide causing no decline in antimicrobial activity even if adsorbed to anionic matter or the like such as a cationic antimicrobial peptide, and to provide antimicrobial agents, sterilizers and preservatives ...
|
|
JP3516681B2 |
We have discovered epitopes of the HCV viral proteins which are immunoreactive with immune serum. The epitopes are useful in immunodiagnostic assays and as immunogens.
|
|
JP3514680B2 |
To obtain the subject new polypeptide consisting of a segment of a specific number of amino acids afforded by a specific amino acid sequence immunoreactive to a hepatitis C virus(HCV) antibody, and useful for e.g. vaccines in reliably di...
|
|
JP3514751B2 |
To provide a vaccine for reliable diagnosis, prognostic intermediary, and prophylaxis and/or therapy for the disease and an immunotherapeutic remedial agent. A polypeptide including a newly characterized HCV epitope, a method of producin...
|
|
JP2004505991A |
The invention relates to novel peptides and their use in assays for identifying novel immunosuppressants. More particularly the present invention provides methods and compositions for identifying compounds that will modulate the interact...
|
|
JP2004501085A |
A process is described for preparing a substrate for the transglycosylase enzymes of bacterial cell wall biosynthesis. The chemical synthesis makes available a sustainable and substantially pure source of supply of lipid II, including an...
|
|
JP2004002441A |
To provide a peptide which forms a linear epitope against a human autoantibody.This peptide is used as an additional diagnostic agent for identifying and classifying an individual which is preliminarily exposed to a specific immunogen or...
|
|
JP3478859B2 |
PURPOSE: To isolate an oligophagous activity inhibitory factor from erythrocyte itself, purify it, confirm its presence, and elucidate its activity. CONSTITUTION: This oligophagous activity inhibitory factor has the following characteris...
|
|
JP3446977B2 |
PURPOSE: To obtain a hair-dyeing agent containing a silylated peptide, little in the damage to hair on its dyeing, holding the hair in a good state, and capable of imparting luster and moisture to the hair after the dyeing. CONSTITUTION:...
|
|
JP2003252896A |
To rapidly synthesis a cyclic peptide which is a functional material by using water as an environmental-friendly and inexpensive reaction solvent.The cyclic peptide having an arbitrary amino acid sequence is synthesized by carrying out a...
|
|
JP3444885B2 |
The invention relates to an immunoglobulin characterized in that it comprises two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, this immunoglobulin being furthe...
|
|
JP2003521448A |
The present invention is directed to polypeptides and peptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three am...
|
|
JP2003517445A |
This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates to peptides derived from homologous seque...
|
|
JP3383307B2 |
The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separatio...
|
|
JP3357163B2 |
Stabilized composition of troponin I or T for immunoassays, comprising an aqueous solution containing troponin I or troponin T, 1 to 10 molar equivalents of troponin C per molar equivalent of troponin I or T, and Mg++ and/or Ca++ ions, a...
|
|
JP2002534996A |
(57) [Summary] The present invention relates to a relatively short peptide (referred to herein as α-conotoxin) having a length of about 10-30 residues, which is naturally available in trace amounts in the cone snail venom. , Or with res...
|
|
JP2002530273A |
This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating m...
|
|
JP2002522505A |
The present invention provides methods and kits for increasing blood flow to ischemic tissue, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, ...
|
|
JP2002518451A |
Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...
|
|
JP2002517459A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002517442A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002517458A |
(57) [Summary] Methods for synthesizing large collections of diverse multimeric compounds and iterative processes for assessing key molecular constraints that confer multibinding properties on multimeric compounds are disclosed. A librar...
|
|
JP2002517461A |
Disclosed are multibinding compounds which are bradykinin antagonists. The multibinding compounds of this invention contain from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a b...
|
|
JP2002517422A |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
JP2002517460A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002517421A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002517462A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002517457A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002517464A |
Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of eac...
|
|
JP2002517463A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002517465A |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
JP2002517420A |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
JP2002138100A |
To provide a safe food composition having a vasodepressor activity by employing treated peptide as a raw material of food, after decomposing a protein included in Wakame seaweed (Undariapiuna tifida) by proteolytic enzyme into a peptide ...
|
|
JP2002512986A |
Novel membrane-forming amphiphilic lipopeptides comprising one or more peptide moieties containing 2-50 aminoacyl residues and one or more hydrocarbon chains containing 5-50 carbon atoms. Such lipopeptides may be used in the formation of...
|
|
JP2002512368A |
The ability of a query compound to modulate the biological activity of a receptor in a multicellular organism is predicted on the basis of its interaction with that receptor in the presence of various member of a panel of BioKeys. The Bi...
|
|
JP2002512590A |
The present invention provides anti-tumor peptides of Formula I,A-B-NR3-CHD-CH(OCH3)-CH2CO-E-K(I),and the acid salts thereof. A is an amino acid residue selected from the group consisting of N-methyl-D-prolyl, N-methyl-D-homoprolyl and N...
|
|
JP2002510051A |
The invention provides methods for identifying agents that are ligands for nuclear receptors. The methods include conducting multiplexed assays utilizing positive hybrid systems, reverse hybrid systems, direct interaction assays and othe...
|
|
JP2002509859A |
Peptides which bind to HLA-A29 molecules are disclosed. These molecules satisfy motifs defined by SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25. Also described are minigenes which encode the peptides of the invention as well as their use.
|
|
JP3261383B2 |
DNA encoding a novel human beta 2 integrin alpha subunit polypeptide, designated alpha d, is disclosed along with methods and materials for production of the same by recombinant procedures. Fusion proteins are also disclosed which includ...
|
|
JP2002503811A |
The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and p...
|
|
JP2002503231A |
Methods for determining an optimal binding motif for a binding compound are provided in which the binding compound is contacted with an oriented degenerate cyclic peptide library (ODCPL) under conditions which allow for interaction betwe...
|
|
JP2002501079A |
The present invention relates to peptides that are more potent than or equally potent as the conventional antimicrobial peptides and has strong antimicrobial activities at high salt concentration.
|
|
JP2001348400A |
To provide an effective treatment of a disorder and disease caused by various kinds of neurophysiology by increasing the free CRF level by utilizing a relationship between the decreased CRF level and such diseases.This ligand inhibitor o...
|
|
JP2001524944A |
(57) [Summary] The present invention provides a method for relieving a subject's neuropathic pain by administering a neuropathic pain-relieving amount of a prosaposin receptor agonist to the subject. The present invention also provides a...
|
|
JP2001520639A |
The invention is directed to antimicrobial peptides related to naturally-occurring protegrin peptides, and methods of using the peptides in a variety of contexts, including the treatment or prevention of infections.
|
|
JP2001278809A |
To provide a relatively low-molecular peptide usable in screening diagnostics or therapeutic agents for various diseases caused by the abnormal activation of macrophage or microglia. The subject method is characterized by comprising usin...
|
|
JP3213942B2 |
Substances of polypeptide nature are obtainable by extraction with HClO4 and 3M KCl from animal tissue homogenates. The substances have the characteristics of (a) molecular weights ranging from 10,000 to 50,000 daltons (by polyacrylamide...
|
|
JP2001510995A |
A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadamia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to...
|
|
JP2001211895A |
To obtain an oligopeptide derived from the residues of a domestic animal or a fish, most suitable for a health food having an active oxygen free radical elimination activity and angiotensin-I-converting enzyme inhibition activity, and pr...
|
